Literature DB >> 9546959

Carnitines increase plasma levels of adenosine and ATP in humans.

P L Capecchi1, F Laghi Pasini, E Quartarolo, T Di Perri.   

Abstract

In order to help to clarify the mode of action of carnitine derivatives, plasma levels of adenosine, ATP and inosine were evaluated following the infusion of 0.75, 0.50 and 0.25 mg/kg/min propionyl-L-carnitine (PLC) for 30 min in patients affected with peripheral arterial disease. Moreover, the effects of 0.75 mg/kg/min acetyl-L-carnitine (ALC) and L-carnitine (LC) were studied in the same conditions. Finally, the activity of 7.5 mg/kg/min PLC administered for 3 min was also evaluated. PLC and ALC produced a significant increase in plasma levels of adenosine and ATP, whereas LC induced less relevant changes. The administration of the compounds did not affect the adenosine/inosine ratio. Peak plasma levels of adenosine preceded in any case those of ATP. The possibility can be suggested that the pharmacological activity of PLC, ALC, and LC may be mediated, at least in part, by an interference with the endogenous purine system. Since these effects may be related to physiological mechanisms of tissue protection, new pharmacological perspectives for the compounds may arise.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9546959     DOI: 10.1177/1358863X9700200201

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  2 in total

1.  A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression.

Authors:  Brian P Brennan; John Eric Jensen; James I Hudson; Caitlin E Coit; Ashley Beaulieu; Harrison G Pope; Perry F Renshaw; Bruce M Cohen
Journal:  J Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.153

2.  Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels.

Authors:  Sirakarnt Dhitavat; Daniela Ortiz; Thomas B Shea; Ezequiel R Rivera
Journal:  Neurochem Res       Date:  2002-06       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.